Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 304 adjuvant daraxonrasib versus observation in resected PDAC
jRCT2031250809Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jun 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Daraxonrasib with Standard-of-care observation (2 arms). Primary endpoint: Disease-free survival per investigator. Started Jun 2026; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031250809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250809.